Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Q32 Bio Inc. QTTB

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$53.7M
$29.8M
$-33.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Its most advanced product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart: SIGNAL-AA Part A for the treatment of alopecia areata, and SIGNAL-AD for the treatment of atopic dermatitis. The company was incorporated under the laws of the State of Delaware on April 10, 2017, and its principal executive office is located at 830 Winter Street, Waltham, Massachusetts. As of December 31, 2025, the company had 24 full-time employees, of which 3 have M.D. or Ph.D. degrees, with 13 employees engaged in research and development and 11 in general management and administration.

Written from the business description in Q32 Bio Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 10 March 2026. Every sentence was checked against that document before publication.

Growth

USD 53.7M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 53.7 · Net income 29.8
20M40M-50M-100M
2017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

55 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 31.5% · Net 55.5%
-2000%-4000%-6000%
201720212025
ROE
FY2025 · ROE 125.1%
50%100%-20%-40%
201720212025
Three returns, three denominators.

Each USD of equity produced 125 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -33.5
-50M-100M
201720212025

Total assetsUSD 61.8M
EquityUSD 42.0M
CashUSD 48.3M
Current ratio4.85×

Equity funds 68% of total assets.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
QTTB, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.10.0−0.00.00.00.00.00.0◌
Operating income $B0.0−0.1−0.0−0.1−0.1−0.1−0.1−0.1−0.0
EBITDA $B0.0−0.1−0.0−0.1−0.1−0.1−0.1−0.1−0.0
Income tax $B0.00.00.00.00.00.00.00.00.0
Net income $B0.0−0.0−0.1−0.0−0.1−0.1−0.1−0.1−0.0
Free cash flow $B−0.0−0.1−0.0−0.1−0.1−0.1−0.1−0.10.0
EPS, diluted $2.42−6.58−153.96−0.09−1.73−2.80−2.47−1.95−12.10
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %125.1———−52.4−56.6−45.7——
Shares out B0.010.010.000.060.060.050.050.040.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 36 reconciliationsAUDITED

Reconciled in 9 of the 9 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image